Revolution Medicines (RVMDW) Projected to Post Quarterly Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMDW) is projected to issue its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($1.5782) per share and revenue of $3.8940 million for the quarter.

Revolution Medicines Trading Down 2.7%

Shares of RVMDW stock opened at $1.80 on Monday. Revolution Medicines has a 1-year low of $0.03 and a 1-year high of $3.59. The stock’s fifty day simple moving average is $1.71 and its 200-day simple moving average is $0.86.

Revolution Medicines Company Profile

Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.

Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.